Search

Your search keyword '"Van Veldhuisen, Dirk J"' showing total 4,046 results
Start Over Author "Van Veldhuisen, Dirk J"
4,046 results on '"Van Veldhuisen, Dirk J"'

51. Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure

Author

Horiuchi, Yu, Wettersten, Nicholas, van Veldhuisen, Dirk J., Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael C., Cannon, Chad M., Müeller, Gerhard A., Birkhahn, Robert, Taub, Pam, Vilke, Gary M., Barnett, Olga, McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, Maisel, Alan, and Murray, Patrick T.

Published
2021
Full Text
View/download PDF

52. Incidence and Outcomes of Pneumonia in Patients With Heart Failure

Author

Shen, Li, Jhund, Pardeep S., Anand, Inder S., Bhatt, Ankeet S., Desai, Akshay S., Maggioni, Aldo P., Martinez, Felipe A., Pfeffer, Marc A., Rizkala, Adel R., Rouleau, Jean L., Swedberg, Karl, Vaduganathan, Muthiah, Vardeny, Orly, van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., Packer, Milton, Solomon, Scott D., and McMurray, John J.V.

Published
2021
Full Text
View/download PDF

53. Impact of Geographic Region on the COMMANDER-HF Trial

Author

Ferreira, João Pedro, Cleland, John G.F., Lam, Carolyn S.P., van Veldhuisen, Dirk J., Byra, William M., La Police, David A., Anker, Stefan D., Mehra, Mandeep R., Leroy, Céline, Eschwege, Valerie, Toussaint-Hacquard, Marie, Rossignol, Patrick, Greenberg, Barry, and Zannad, Faiez

Published
2021
Full Text
View/download PDF

54. Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial

Author

Liu, Licette CY, Valente, Mattia AE, Postmus, Douwe, O’Connor, Christopher M, Metra, Marco, Dittrich, Howard C, Ponikowski, Piotr, Teerlink, John R, Cotter, Gad, Davison, Beth, Cleland, John GF, Givertz, Michael M, Bloomfield, Daniel M, van Veldhuisen, Dirk J, Hillege, Hans L, van der Meer, Peter, and Voors, Adriaan A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Clinical Research, Heart Disease, Acute Disease, Aged, Biomarkers, Diuretics, Female, Heart Failure, Humans, Male, Xanthines, Acute heart failure, Treatment heterogeneity, Subpopulation treatment effect pattern plot, Rolofylline, Pharmacology and Pharmaceutical Sciences, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Pharmacology and pharmaceutical sciences
Abstract

BackgroundOver the last 50 years, clinical trials of novel interventions for acute heart failure (AHF) have, with few exceptions, been neutral or shown harm. We hypothesize that this might be related to a differential response to pharmacological therapy.MethodsWe studied the magnitude of treatment effect of rolofylline across clinical characteristics and plasma biomarkers in 2033 AHF patients and derived a biomarker-based responder sum score model. Treatment response was survival from all-cause mortality through day 180.ResultsIn the overall study population, rolofylline had no effect on mortality (HR 1.03, 95% CI 0.82-1.28, p = 0.808). We found no treatment interaction across clinical characteristics, but we found interactions between several biomarkers and rolofylline. The biomarker-based sum score model included TNF-R1α, ST2, WAP four-disulfide core domain protein HE4 (WAP-4C), and total cholesterol, and the score ranged between 0 and 4. In patients with score 4 (those with increased TNF-R1α, ST2, WAP-4C, and low total cholesterol), treatment with rolofylline was beneficial (HR 0.61, 95% CI 0.40-0.92, p = 0.019). In patients with score 0, treatment with rolofylline was harmful (HR 5.52, 95% CI 1.68-18.13, p = 0.005; treatment by score interaction p

Published
2017

59. Association of fibrotic markers with diastolic function after STEMI

Author

Circulatory Health, Gezonde Vaten, Al Ali, Lawien, Meijers, Wouter C., Beldhuis, Iris E., Groot, Hilde E., Lipsic, Erik, van Veldhuisen, Dirk J., Voors, Adriaan A., van der Horst, Iwan C.C., de Boer, Rudolf A., van der Harst, Pim, Circulatory Health, Gezonde Vaten, Al Ali, Lawien, Meijers, Wouter C., Beldhuis, Iris E., Groot, Hilde E., Lipsic, Erik, van Veldhuisen, Dirk J., Voors, Adriaan A., van der Horst, Iwan C.C., de Boer, Rudolf A., and van der Harst, Pim

Published
2024

60. Serum Calcification Propensity Is Increased in Myocardial Infarction and Hints at a Pathophysiological Role Independent of Classical Cardiovascular Risk Factors

Author

Cardiologie, Gezonde Vaten, Circulatory Health, Mencke, Rik, Al Ali, Lawien, De Koning, Marie Sophie L.Y., Pasch, Andreas, Minnion, Magdalena, Feelisch, Martin, Van Veldhuisen, Dirk J., Van Der Horst, Iwan C.C., Gansevoort, Ron T., Bakker, Stephan J.L., De Borst, Martin H., Van Goor, Harry, Van Der Harst, Pim, Lipsic, Erik, Hillebrands, Jan Luuk, Cardiologie, Gezonde Vaten, Circulatory Health, Mencke, Rik, Al Ali, Lawien, De Koning, Marie Sophie L.Y., Pasch, Andreas, Minnion, Magdalena, Feelisch, Martin, Van Veldhuisen, Dirk J., Van Der Horst, Iwan C.C., Gansevoort, Ron T., Bakker, Stephan J.L., De Borst, Martin H., Van Goor, Harry, Van Der Harst, Pim, Lipsic, Erik, and Hillebrands, Jan Luuk

Published
2024

61. Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction:Results of the Amylo-VIP-HF study

Author

Tubben, Alwin, Tingen, Hendrea S. A., Prakken, Niek H. J., van Empel, Vanessa P. M., Gorter, Thomas M., Meems, Laura M. G., Manintveld, Olivier C., Rienstra, Michiel, Tieleman, Robert G., Glaudemans, Andor W. J. M., van Veldhuisen, Dirk J., Slart, Riemer H. J. A., Nienhuis, Hans L. A., van der Meer, Peter, Tubben, Alwin, Tingen, Hendrea S. A., Prakken, Niek H. J., van Empel, Vanessa P. M., Gorter, Thomas M., Meems, Laura M. G., Manintveld, Olivier C., Rienstra, Michiel, Tieleman, Robert G., Glaudemans, Andor W. J. M., van Veldhuisen, Dirk J., Slart, Riemer H. J. A., Nienhuis, Hans L. A., and van der Meer, Peter

Published
2024

63. Serum Calcification Propensity Is Increased in Myocardial Infarction and Hints at a Pathophysiological Role Independent of Classical Cardiovascular Risk Factors.

Author

Mencke, Rik, Al Ali, Lawien, de Koning, Marie-Sophie L. Y., Pasch, Andreas, Minnion, Magdalena, Feelisch, Martin, van Veldhuisen, Dirk J., van der Horst, Iwan C. C., Gansevoort, Ron T., Bakker, Stephan J. L., de Borst, Martin H., van Goor, Harry, van der Harst, Pim, Lipsic, Erik, and Hillebrands, Jan-Luuk

Published
2024
Full Text
View/download PDF

66. Distinct Pathological Pathways in Patients With Heart Failure and Diabetes

Author

Tromp, Jasper, Voors, Adriaan A., Sharma, Abhinav, Ferreira, João P., Ouwerkerk, Wouter, Hillege, Hans L., Gomez, Karla A., Dickstein, Kenneth, Anker, Stefan D., Metra, Marco, Lang, Chim C., Ng, Leong L., van der Harst, Pim, van Veldhuisen, Dirk J., van der Meer, Peter, Lam, Carolyn S.P., Zannad, Faiez, and Sama, Iziah E.

Published
2020
Full Text
View/download PDF

68. A combined clinical and biomarker approach to predict diuretic response in acute heart failure

Author

ter Maaten, Jozine M, Valente, Mattia AE, Metra, Marco, Bruno, Noemi, O’Connor, Christopher M, Ponikowski, Piotr, Teerlink, John R, Cotter, Gad, Davison, Beth, Cleland, John G, Givertz, Michael M, Bloomfield, Daniel M, Dittrich, Howard C, van Veldhuisen, Dirk J, Hillege, Hans L, Damman, Kevin, and Voors, Adriaan A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Heart Disease, Kidney Disease, Prevention, Cardiovascular, Clinical Research, Acute Disease, Atherosclerosis, Biomarkers, Clinical Trials, Phase III as Topic, Diuretics, Electrolytes, Furosemide, Heart Failure, Humans, Kidney Diseases, Randomized Controlled Trials as Topic, Retrospective Studies, Time Factors, Treatment Outcome, Diuretic response, Heart failure, Prediction, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundPoor diuretic response in acute heart failure is related to poor clinical outcome. The underlying mechanisms and pathophysiology behind diuretic resistance are incompletely understood. We evaluated a combined approach using clinical characteristics and biomarkers to predict diuretic response in acute heart failure (AHF).Methods and resultsWe investigated explanatory and predictive models for diuretic response--weight loss at day 4 per 40 mg of furosemide--in 974 patients with AHF included in the PROTECT trial. Biomarkers, addressing multiple pathophysiological pathways, were determined at baseline and after 24 h. An explanatory baseline biomarker model of a poor diuretic response included low potassium, chloride, hemoglobin, myeloperoxidase, and high blood urea nitrogen, albumin, triglycerides, ST2 and neutrophil gelatinase-associated lipocalin (r(2) = 0.086). Diuretic response after 24 h (early diuretic response) was a strong predictor of diuretic response (β = 0.467, P < 0.001; r(2) = 0.523). Addition of diuretic response after 24 h to biomarkers and clinical characteristics significantly improved the predictive model (r(2) = 0.586, P < 0.001).ConclusionsBiomarkers indicate that diuretic unresponsiveness is associated with an atherosclerotic profile with abnormal renal function and electrolytes. However, predicting diuretic response is difficult and biomarkers have limited additive value. Patients at risk of poor diuretic response can be identified by measuring early diuretic response after 24 h.

Published
2016

69. Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF

Author

Adamo, Marianna, primary, Pagnesi, Matteo, additional, Di Pasquale, Mattia, additional, Ravera, Alice, additional, Dickstein, Kenneth, additional, Ng, Leong L., additional, Anker, Stefan D., additional, Cleland, John G., additional, Filippatos, Gerasimos S., additional, Lang, Chim C., additional, Ponikowski, Piotr, additional, Samani, Nilesh J., additional, Zannad, Faiez, additional, van Veldhuisen, Dirk J., additional, Lipsic, Erik, additional, Voors, Adriaan, additional, and Metra, Marco, additional

Published
2023
Full Text
View/download PDF

70. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

Author

Kotecha, Dipak, Gill, Simrat K., Flather, Marcus D., Holmes, Jane, Packer, Milton, Rosano, Giuseppe, Böhm, Michael, McMurray, John J.V., Wikstrand, John, Anker, Stefan D., van Veldhuisen, Dirk J., Manzano, Luis, von Lueder, Thomas G., Rigby, Alan S., Andersson, Bert, Kjekshus, John, Wedel, Hans, Ruschitzka, Frank, Cleland, John G.F., Damman, Kevin, Redon, Josep, and Coats, Andrew J.S.

Published
2019
Full Text
View/download PDF

72. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction

Author

ter Maaten, Jozine M., Martens, Pieter, Damman, Kevin, Dickstein, Kenneth, Ponikowski, Piotr, Lang, Chim C., Ng, Leong L., Anker, Stefan D., Samani, Nilesh J., Filippatos, Gerasimos, Cleland, John G., Zannad, Faiez, Hillege, Hans L., van Veldhuisen, Dirk J., Metra, Marco, Voors, Adriaan A., and Mullens, Wilfried

Published
2020
Full Text
View/download PDF

74. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

Author

Santema, Bernadet T., Chan, Michelle M. Y., Tromp, Jasper, Dokter, Martin, van der Wal, Haye H., Emmens, Johanna E., Takens, Janny, Samani, Nilesh J., Ng, Leong L., Lang, Chim C., van der Meer, Peter, ter Maaten, Jozine M., Damman, Kevin, Dickstein, Kenneth, Cleland, John G., Zannad, Faiez, Anker, Stefan D., Metra, Marco, van der Harst, Pim, de Boer, Rudolf A., van Veldhuisen, Dirk J., Rienstra, Michiel, Lam, Carolyn S. P., and Voors, Adriaan A.

Published
2020
Full Text
View/download PDF

75. Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

Author

Zannad, Faiez, Greenberg, Barry, Cleland, John GF, Gheorghiade, Mihai, van Veldhuisen, Dirk J, Mehra, Mandeep R, Anker, Stefan D, Byra, William M, Fu, Min, and Mills, Roger M

Subjects
Clinical Trials and Supportive Activities, Patient Safety, Heart Disease, Cardiovascular, Clinical Research, Heart Disease - Coronary Heart Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Administration, Oral, Coronary Artery Disease, Double-Blind Method, Factor Xa Inhibitors, Heart Failure, Humans, Myocardial Infarction, Prospective Studies, Research Design, Risk Factors, Rivaroxaban, Stroke, Survival Rate, rivaroxaban, thrombin, antithrombotic, heart failure, coronary artery disease, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

AimsThrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after an exacerbation of HF in patients with reduced ejection fraction (HF-rEF) and documented coronary artery disease.MethodsThis is an international prospective, multicentre, randomized, double-blind, placebo-controlled, event-driven study of approximately 5000 patients for a targeted 984 events. Patients must have a recent symptomatic exacerbation of HF, increased plasma concentrations of natriuretic peptides (B-type natriuretic peptide ≥200 pg/mL or N-terminal pro-B-type natriuretic peptide ≥800 pg/mL), with left ventricular ejection fraction ≤40% and coronary artery disease. Patients requiring anticoagulation for atrial fibrillation or other conditions will be excluded. After an index event (overnight hospitalization, emergency department or observation unit admission, or unscheduled outpatient parenteral treatment for worsening HF), patients will be randomized 1:1 to rivaroxaban or placebo (with standard of care). The primary efficacy outcome event is a composite of all-cause mortality, myocardial infarction or stroke. The principal safety outcome events are the composite of fatal bleeding or bleeding into a critical space with potential permanent disability, bleeding events requiring hospitalization and major bleeding events according to International Society on Thrombosis and Haemostasis bleeding criteria.ConclusionCOMMANDER HF is the first prospective study of a target-specific oral antithrombotic agent in HF. It will provide important information regarding rivaroxaban use following an HF event in an HF-rEF patient population with coronary artery disease.

Published
2015

77. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

Author

Chandra, Alvin, Vaduganathan, Muthiah, Lewis, Eldrin F., Claggett, Brian L., Rizkala, Adel R., Wang, Wenyan, Lefkowitz, Martin P., Shi, Victor C., Anand, Inder S., Ge, Junbo, Lam, Carolyn S.P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Pfeffer, Marc A., Pieske, Burkert, Redfield, Margaret M., Rouleau, Jean L., Van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., McMurray, John J.V., and Solomon, Scott D.

Published
2019
Full Text
View/download PDF

78. Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS)

Author

Murray, Patrick T., Wettersten, Nicholas, van Veldhuisen, Dirk J., Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael C., Cannon, Chad M., Müeller, Gerhard A., Birkhahn, Robert, Horiuchi, Yu, Clopton, Paul, Taub, Pam, Vilke, Gary M., Barnett, Olga, McDonald, Kenneth, Mahon, Niall, NuÑez, Julio, Briguori, Carlo, Passino, Claudio, and Maisel, Alan

Published
2019
Full Text
View/download PDF

79. Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial

Author

Piccini, Jonathan P., Abraham, William T., Dufton, Christopher, Carroll, Ian A., Healey, Jeff S., van Veldhuisen, Dirk J., Sauer, William H., Anand, Inder S., White, Michel, Wilton, Stephen B., Aleong, Ryan, Rienstra, Michiel, Krueger, Steven K., Ayala-Paredes, Felix, Khaykin, Yaariv, Merkely, Bela, Miloradović, Vladimir, Wranicz, Jerzy K., Ilkhanoff, Leonard, Ziegler, Paul D., Davis, Gordon, Emery, Laura L., Marshall, Debra, Kao, David P., Bristow, Michael R., and Connolly, Stuart J.

Published
2019
Full Text
View/download PDF

81. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

Author

Gheorghiade, Mihai, Vaduganathan, Muthiah, Greene, Stephen J, Mentz, Robert J, Adams, Kirkwood F, Anker, Stefan D, Arnold, Malcolm, Baschiera, Fabio, Cleland, John GF, Cotter, Gadi, Fonarow, Gregg C, Giordano, Christopher, Metra, Marco, Misselwitz, Frank, Mühlhofer, Eva, Nodari, Savina, Frank Peacock, W, Pieske, Burkert M, Sabbah, Hani N, Sato, Naoki, Shah, Monica R, Stockbridge, Norman L, Teerlink, John R, van Veldhuisen, Dirk J, Zalewski, Andrew, Zannad, Faiez, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Cardiovascular, Heart Disease, Clinical Trials and Supportive Activities, Clinical Trials as Topic, Heart Failure, Hospitalization, Humans, Inpatients, Patient Selection, Research Design, Therapies, Investigational, United States, Heart failure, Site selection, Clinical trials, FDA, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

There are over 1 million hospitalizations for heart failure (HF) annually in the United States alone, and a similar number has been reported in Europe. Recent clinical trials investigating novel therapies in patients with hospitalized HF (HHF) have been negative, and the post-discharge event rate remains unacceptably high. The lack of success with HHF trials stem from problems with understanding the study drug, matching the drug to the appropriate HF subgroup, and study execution. Related to the concept of study execution is the importance of including appropriate study sites in HHF trials. Often overlooked issues include consideration of the geographic region and the number of patients enrolled at each study center. Marked differences in baseline patient co-morbidities, serum biomarkers, treatment utilization and outcomes have been demonstrated across geographic regions. Furthermore, patients from sites with low recruitment may have worse outcomes compared to sites with higher enrollment patterns. Consequently, sites with poor trial enrollment may influence key patient end points and likely do not justify the costs of site training and maintenance. Accordingly, there is an unmet need to develop strategies to identify the right study sites that have acceptable patient quantity and quality. Potential approaches include, but are not limited to, establishing a pre-trial registry, developing site performance metrics, identifying a local regionally involved leader and bolstering recruitment incentives. This manuscript summarizes the roundtable discussion hosted by the Food and Drug Administration between members of academia, the National Institutes of Health, industry partners, contract research organizations and academic research organizations on the importance of selecting optimal sites for successful trials in HHF.

Published
2014

82. Digoxin Use and Lower 30-day All-cause Readmission for Medicare Beneficiaries Hospitalized for Heart Failure

Author

Ahmed, Ali, Bourge, Robert C, Fonarow, Gregg C, Patel, Kanan, Morgan, Charity J, Fleg, Jerome L, Aban, Inmaculada B, Love, Thomas E, Yancy, Clyde W, Deedwania, Prakash, van Veldhuisen, Dirk J, Filippatos, Gerasimos S, Anker, Stefan D, and Allman, Richard M

Subjects
Clinical Research, Aging, Heart Disease, Cardiovascular, Aged, Aged, 80 and over, Cardiotonic Agents, Case-Control Studies, Chronic Disease, Digoxin, Drug Administration Schedule, Female, Heart Failure, Systolic, Humans, Male, Medicare, Patient Discharge, Patient Readmission, Treatment Outcome, United States, Heart failure, Hospital readmission, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundHeart failure is the leading cause for hospital readmission, the reduction of which is a priority under the Affordable Care Act. Digoxin reduces 30-day all-cause hospital admission in chronic systolic heart failure. Whether digoxin is effective in reducing readmission after hospitalization for acute decompensation remains unknown.MethodsOf the 5153 Medicare beneficiaries hospitalized for acute heart failure and not receiving digoxin, 1054 (20%) received new discharge prescriptions for digoxin. Propensity scores for digoxin use, estimated for each of the 5153 patients, were used to assemble a matched cohort of 1842 (921 pairs) patients (mean age, 76 years; 56% women; 25% African American) receiving and not receiving digoxin, who were balanced on 55 baseline characteristics.ResultsThirty-day all-cause readmission occurred in 17% and 22% of matched patients receiving and not receiving digoxin, respectively (hazard ratio [HR] for digoxin, 0.77; 95% confidence interval [CI], 0.63-0.95). This beneficial association was observed only in those with ejection fraction

Published
2014

84. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype

Author

Piccini, Jonathan P., Dufton, Christopher, Carroll, Ian A., Healey, Jeff S., Abraham, William T., Khaykin, Yaariv, Aleong, Ryan, Krueger, Steven K., Sauer, William H., Wilton, Stephen B., Rienstra, Michiel, van Veldhuisen, Dirk J., Anand, Inder S., White, Michel, Camm, A. John, Ziegler, Paul D., Marshall, Debra, Bristow, Michael R., and Connolly, Stuart J.

Published
2021
Full Text
View/download PDF

87. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction

Author

Tromp, Jasper, Westenbrink, B. Daan, Ouwerkerk, Wouter, van Veldhuisen, Dirk J., Samani, Nilesh J., Ponikowski, Piotr, Metra, Marco, Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, van der Harst, Pim, Lang, Chim C., Ng, Leong L., Zannad, Faiez, Zwinderman, Aelko H., Hillege, Hans L., van der Meer, Peter, and Voors, Adriaan A.

Published
2018
Full Text
View/download PDF

88. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial

Author

Piccini, Jonathan P., Connolly, Stuart J., Abraham, William T., Healey, Jeff S., Steinberg, Benjamin A., Al-Khalidi, Hussein R., Dignacco, Patricia, van Veldhuisen, Dirk J., Sauer, William H., White, Michel, Wilton, Stephen B., Anand, Inder S., Dufton, Christopher, Marshall, Debra A., Aleong, Ryan G., Davis, Gordon W., Clark, Richard L., Emery, Laura L., and Bristow, Michael R.

Published
2018
Full Text
View/download PDF

92. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure

Author

ter Maaten, Jozine M., Voors, Adriaan A., Damman, Kevin, van der Meer, Peter, Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, van der Harst, Pim, Hillege, Hans L., Lang, Chim C., Metra, Marco, Navis, Gerjan, Ng, Leong, Ouwerkerk, Wouter, Ponikowski, Piotr, Samani, Nilesh J., van Veldhuisen, Dirk J., Zannad, Faiez, Zwinderman, Aeilko H., and de Borst, Martin H.

Published
2018
Full Text
View/download PDF

93. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF

Author

Ouwerkerk, Wouter, Zwinderman, Aeilko H., Ng, Leong L., Demissei, Biniyam, Hillege, Hans L., Zannad, Faiez, van Veldhuisen, Dirk J., Samani, Nilesh J., Ponikowski, Piotr, Metra, Marco, ter Maaten, Jozine M., Lang, Chim C., van der Harst, Pim, Filippatos, Gerasimos, Dickstein, Kenneth, Cleland, John G., Anker, Stefan D., and Voors, Adriaan A.

Published
2018
Full Text
View/download PDF

96. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation

Author

Mordi, Ify R., Santema, Bernadet T., Kloosterman, Mariëlle, Choy, Anna-Maria, Rienstra, Michiel, van Gelder, Isabelle, Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, van der Harst, Pim, Hillege, Hans L., Metra, Marco, Ng, Leong L., Ouwerkerk, Wouter, Ponikowski, Piotr, Samani, Nilesh J., van Veldhuisen, Dirk J., Zwinderman, Aeilko H., Zannad, Faiez, Voors, Adriaan A., and Lang, Chim C.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results